Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim or Pegfilgrastim Secondary Prophylaxis in Early Breast Cancer
NCT00030758Phase 4Unknown
- Sponsor
- Anglo Celtic Cooperative Oncology Group
- Start
- Oct 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgrastim and pegfilgrastim in neutropenia (2 arms), sponsored by Anglo Celtic Cooperative Oncology Group. Primary endpoints: Proportion of patients achieving ≥ 85% of planned dose intensity and Proportion of patients with ≥ 1 neutropenic event. Status: unknown.
02
Drugs
filgrastimpegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00030758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030758.